P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine

Molecular Pharmacology

Volumn 82, Issue 4, 2012, Pages 636-644

  Lagas, Jurjen S ^a,b   Damen, Carola W N ^b   Van Waterschoot, Robert A B ^a   Iusuf, Dilek ^a   Beijnen, Jos H ^b   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4' O DEACETYLVINORELBINE; CARBOXYLESTERASE; CYTOCHROME P450 3A; DRUG METABOLITE; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; NAVELBINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DEACETYLATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; IN VITRO STUDY; KNOCKOUT MOUSE; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CARBOXYLESTERASE; CYTOCHROME P-450 CYP3A; DOGS; FEMALE; HUMANS; LOPERAMIDE; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, KNOCKOUT; MICROSOMES, LIVER; NITROPHENOLS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; UP-REGULATION; VINBLASTINE;

EID: 84866851130     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.077099     Document Type: Article

References (39)

1. Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, Robey R, Dwyer A, Goldspiel B, Balis F, et al. (2009) A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 15:3574-3582.
2. Adams DJ and Knick VC (1995) P-glycoprotein mediated resistance to 5′-noranhydro-vinblastine (Navelbine). Invest New Drugs 13:13-21.
3. Beulz-Riché D, Grudé P, Puozzo C, Sautel F, Filaquier C, Riché C, and Ratanasavanh D (2005) Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol 19:545-553.
4. Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, and Pavlidis N (2009) Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15:6454-6461.
5. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, and Akiyama SI (1999) Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 56:1219-1228.
6. Damen CW, Lagas JS, Rosing H, Schellens JH, and Beijnen JH (2009) The bioanalysis of vinorelbine and 4-O-deacetylvinorelbine in human and mouse plasma using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass-spectrometry. Biomed Chromatogr 23:1316-1325.
7. Delord JP, Puozzo C, Lefresne F, and Bugat R (2009) Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors. Anticancer Res 29:553-560.
8. Domenech GH and Vogel CL (2001) A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer 2:113-128. (Pubitemid 32771563)
9. Emoto C, Yamazaki H, Yamasaki S, Shimada N, Nakajima M, and Yokoi T (2000) Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica 30:943-953.
10. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, and Borst P (2000a) Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83:375-383. (Pubitemid 30453579)
11. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, and Borst P (2000b) Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 83:366-374. (Pubitemid 30453578)
12. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, et al. (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) CDNA. J Clin Invest 101:1310-1319. (Pubitemid 28166828)
13. Gralla RJ, Gatzemeier U, Gebbia V, Huber R, O'Brien M, and Puozzo C (2007) Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. Drugs 67:1403-1410. (Pubitemid 47026390)
14. Hirsh V, Desjardins P, Needles BM, Rigas JR, Jahanzeb M, Nguyen L, Zembryki D, and Leopold LH (2007) Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): a randomized phase II trial. Am J Clin Oncol 30:245-251. (Pubitemid 46884143)
15. Holmes RS, Wright MW, Laulederkind SJ, Cox LA, Hosokawa M, Imai T, Ishibashi S, Lehner R, Miyazaki M, Perkins EJ, et al. (2010) Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome 21:427-441.
16. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, and Schinkel AH (2005) MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116:824-829. (Pubitemid 41099717)
17. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, and Grove JR (1999) MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28-33. (Pubitemid 29037364)
18. Kajita J, Kuwabara T, Kobayashi H, and Kobayashi S (2000) CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 28:1121-1127. (Pubitemid 30660369)
19. Kawabe T, Chen ZS, Wada M, Uchiumi T, Ono M, Akiyama S, and Kuwano M (1999) Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (CMOAT/MRP2). FEBS Lett 456:327-331. (Pubitemid 29352317)
20. Lê LH, Moore MJ, Siu LL, Oza AM, MacLean M, Fisher B, Chaudhary A, de Alwis DP, Slapak C, and Seymour L (2005) Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 56:154-160. (Pubitemid 40884270)
21. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, and Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643-1649. (Pubitemid 34070598)
22. Press RR, Buckle T, Beijnen JH, and van Tellingen O (2006) The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. Cancer Chemother Pharmacol 57:819-825.
23. Puozzo C, Ung HL, and Zorza G (2007) A high performance liquid chromatography method for vinorelbine and 4-O-deacetyl vinorelbine: a decade of routine analysis in human blood. J Pharm Biomed Anal 44:144-149. (Pubitemid 46566485)
24. Rossi D, Catalano V, Alessandroni P, Fedeli A, Fedeli SL, Giordani P, Baldelli AM, Casadei V, Ceccolini M, Ugolini M, et al. (2007) A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small-cell lung cancer. Clin Lung Cancer 8:382-385. (Pubitemid 46927890)
25. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking Mdr1-type (drug-transporting) Pglycoproteins. Proc Natl Acad Sci USA 94:4028-4033. (Pubitemid 27180493)
26. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995) Absence of the Mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
27. Schmittgen TD and Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3:1101-1108. (Pubitemid 351818697)
28. Shepard RL, Cao J, Starling JJ, and Dantzig AH (2003) Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103:121-125. (Pubitemid 35424215)
29. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, and Okumura K (2002) Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25:771-778. (Pubitemid 40036714)
30. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, et al. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592. (Pubitemid 350097013)
31. van Tellingen O, Kuijpers A, Beijnen JH, Baselier MR, Burghouts JT, and Nooyen WJ (1992) Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 573:328-332.
32. van Tellingen O, Kuijpers AV, Beijnen JH, Nooijen WJ, and Bult A (1993) Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography. Invest New Drugs 11:141-150. (Pubitemid 23277234)
33. van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, et al. (2009) Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 69:8996-9002.
34. van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, and Schinkel AH (2008) Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 73:1029-1036. (Pubitemid 351397908)
35. Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, et al. (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319-327.
36. Wang J, Williams ET, Bourgea J, Wong YN, and Patten CJ (2011) Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2. Drug Metab Dispos 39:1329-1333.
37. Williams ET, Bacon JA, Bender DM, Lowinger JJ, Guo WK, Ehsani ME, Wang X, Wang H, Qian YW, Ruterbories KJ, et al. (2011) Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human. Drug Metab Dispos 39:2305-2313.
38. Wong M, Balleine RL, Blair EY, McLachlan AJ, Ackland SP, Garg MB, Evans S, Farlow D, Collins M, Rivory LP, et al. (2006) Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 24:2448-2455. (Pubitemid 46630621)
39. Yuan JS, Reed A, Chen F, and Stewart CN Jr (2006) Statistical analysis of real-time PCR data. BMC Bioinformatics 7:85.